Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

317 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic Targets.
Zhang B, Lewis W, Stewart CA, Morris BB, Solis LM, Serrano A, Xi Y, Wang Q, Lopez ER, Concannon K, Heeke S, Tang X, Raso G, Cardnell RJ, Vokes N, Blumenschein G, Elamin Y, Fosella F, Tsao A, Skoulidis F, Hume CB, Sasak K, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Tran H, Zhang J, Gibbons D, Vaporciyan A, Wang J, Park K, Heymach JV, Byers LA, Gay CM, Le X. Zhang B, et al. Among authors: blumenschein g. JTO Clin Res Rep. 2023 Dec 17;5(2):100623. doi: 10.1016/j.jtocrr.2023.100623. eCollection 2024 Feb. JTO Clin Res Rep. 2023. PMID: 38357092 Free PMC article.
Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial.
Liu Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Skoulidis F, Chang JY, Liao Z, Gomez DR, O'Reilly M, Heymach JV, Tsao AS, Lin SH. Liu Y, et al. Among authors: blumenschein g. Lung Cancer. 2022 Dec;174:112-117. doi: 10.1016/j.lungcan.2022.10.006. Epub 2022 Oct 29. Lung Cancer. 2022. PMID: 36371941 Clinical Trial.
Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma.
Ferrarotto R, Sousa LG, Feng L, Mott F, Blumenschein G, Altan M, Bell D, Bonini F, Li K, Marques-Piubelli ML, Dal Lago EA, Johnson JJ, Mitani Y, Godoy M, Lee A, Kupferman M, Hanna E, Glisson BS, Elamin Y, El-Naggar A. Ferrarotto R, et al. Among authors: blumenschein g. J Clin Oncol. 2023 May 20;41(15):2843-2851. doi: 10.1200/JCO.22.02221. Epub 2023 Mar 10. J Clin Oncol. 2023. PMID: 36898078 Free PMC article. Clinical Trial.
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial.
Cascone T, Leung CH, Weissferdt A, Pataer A, Carter BW, Godoy MCB, Feldman H, William WN Jr, Xi Y, Basu S, Sun JJ, Yadav SS, Rojas Alvarez FR, Lee Y, Mishra AK, Chen L, Pradhan M, Guo H, Sinjab A, Zhou N, Negrao MV, Le X, Gay CM, Tsao AS, Byers LA, Altan M, Glisson BS, Fossella FV, Elamin YY, Blumenschein G Jr, Zhang J, Skoulidis F, Wu J, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Rajaram R, Antonoff MB, Fujimoto J, Solis LM, Parra ER, Haymaker C, Wistuba II, Swisher SG, Vaporciyan AA, Lin HY, Wang J, Gibbons DL, Jack Lee J, Ajami NJ, Wargo JA, Allison JP, Sharma P, Kadara H, Heymach JV, Sepesi B. Cascone T, et al. Among authors: blumenschein g jr. Nat Med. 2023 Mar;29(3):593-604. doi: 10.1038/s41591-022-02189-0. Epub 2023 Mar 16. Nat Med. 2023. PMID: 36928818 Free PMC article. Clinical Trial.
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Akhave NS, Zhou T, Delasos L, Hicks JK, Aldea M, Minuti G, Hines J, Aredo JV, Dennis MJ, Chakrabarti T, Scott SC, Bironzo P, Scheffler M, Christopoulos P, Stenzinger A, Riess JW, Kim SY, Goldberg SB, Li M, Wang Q, Qing Y, Ni Y, Do MT, Lee R, Ricciuti B, Alessi JV, Wang J, Resuli B, Landi L, Tseng SC, Nishino M, Digumarthy SR, Rinsurongkawong W, Rinsurongkawong V, Vaporciyan AA, Blumenschein GR, Zhang J, Owen DH, Blakely CM, Mountzios G, Shu CA, Bestvina CM, Garassino MC, Marrone KA, Gray JE, Patel SP, Cummings AL, Wakelee HA, Wolf J, Scagliotti GV, Cappuzzo F, Barlesi F, Patil PD, Drusbosky L, Gibbons DL, Meric-Bernstam F, Lee JJ, Heymach JV, Hong DS, Heist RS, Awad MM, Skoulidis F. Negrao MV, et al. Among authors: blumenschein gr. Cancer Discov. 2023 Jul 7;13(7):1556-1571. doi: 10.1158/2159-8290.CD-22-1420. Cancer Discov. 2023. PMID: 37068173 Free PMC article.
Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial.
Altan M, Wang Y, Song J, Welsh J, Tang C, Guha-Thakurta N, Blumenschein GR, Carter BW, Wefel JS, Ghia AJ, Yeboa DN, McAleer MF, Chung C, Woodhouse KD, McGovern SL, Wang C, Kim BYS, Weinberg JS, Briere TM, Elamin YY, Le X, Cascone T, Negrao MV, Skoulidis F, Ferrarotto R, Heymach JV, Li J. Altan M, et al. J Immunother Cancer. 2023 Jul;11(7):e006871. doi: 10.1136/jitc-2023-006871. J Immunother Cancer. 2023. PMID: 37402581 Free PMC article. Clinical Trial.
Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial.
Chang JY, Lin SH, Dong W, Liao Z, Gandhi SJ, Gay CM, Zhang J, Chun SG, Elamin YY, Fossella FV, Blumenschein G, Cascone T, Le X, Pozadzides JV, Tsao A, Verma V, Welsh JW, Chen AB, Altan M, Mehran RJ, Vaporciyan AA, Swisher SG, Balter PA, Fujimoto J, Wistuba II, Feng L, Lee JJ, Heymach JV. Chang JY, et al. Among authors: blumenschein g. Lancet. 2023 Sep 9;402(10405):871-881. doi: 10.1016/S0140-6736(23)01384-3. Epub 2023 Jul 18. Lancet. 2023. PMID: 37478883 Free PMC article. Clinical Trial.
Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC.
Wang K, Du R, Roy-Chowdhuri S, Li ZT, Hong L, Vokes N, Elamin YY, Hume CB, Skoulidis F, Gay CM, Blumenschein G, Fossella FV, Tsao A, Zhang J, Karachaliou N, O'Brate A, Gann CN, Lewis J, Rinsurongkawong W, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Altan M, Le X. Wang K, et al. Among authors: blumenschein g. JTO Clin Res Rep. 2023 Jun 1;4(8):100533. doi: 10.1016/j.jtocrr.2023.100533. eCollection 2023 Aug. JTO Clin Res Rep. 2023. PMID: 37649681 Free PMC article.
Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy.
Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Kim ST, et al. Among authors: blumenschein gr. Nat Commun. 2024 Jul 4;15(1):5621. doi: 10.1038/s41467-024-49733-9. Nat Commun. 2024. PMID: 38965214 Free PMC article. No abstract available.
317 results